Vesicare (solifenacin succinate) tablets Information for Healthcare Professionals
Information for Consumers
 
 
 
WHAT IS OAB? TREATING OAB ABOUT VESIcare PATIENTS ON VESIcare PROFESSIONAL RESOURCES
Goals Approach        
Treating OAB
Approach
It is important that you help your OAB patients to understand that optimal treatment results—for both behavioral and pharmacological therapies—may not manifest for weeks. To give the treatment a full opportunity to work, your patients must be dedicated to active participation in the therapy, and should stay with the course that you outline unless adverse reactions or effects dictate its discontinuation.The symptoms of OAB are chronic, and effective treatment is needed to help patients.10

Behavioral, or nonpharmacological, treatments include the following:11-14

  • Patient education: Helping your patients understand that OAB is a physiologic malfunction rather than a “normal” aspect of aging may encourage them to stay with their treatments and help relieve some of the shame associated with OAB.
  • Diary tracking: Instructing your patients to keep a diary of their fluid intake and OAB symptoms creates an opportunity for you to review the patients’ behavior and point out where changes can be made to help relieve symptoms.
  • Behavior modification: Instructing your patients avoid such bladder irritants as caffeine, citrus fruits and juices, alcohol, sodas, and artificial sweeteners, and reminding them to limit their fluid intake before bed, may help to relieve some OAB symptoms.
  • Pelvic floor exercises: Also called Kegel exercises, voluntary contractions of the pelvic floor muscles strengthens them, and may provide some incontinence relief for some patients.
  • Bladder training: Patients on a regimen of bladder training void at specified intervals. This regimen of scheduled voiding is meant to increase bladder capacity and thus reduce OAB symptoms. Over time, the interval can be gradually increased by 15 minutes until the goal of voiding once every two to four hours is reached.
vesicarerx.com
Learn more about VESIcare with an interactive online experience. Click here.
Patient Resources
VESIcare can help you and your patients address overactive bladder together. The Fresh Approach Kit includes a bladder checklist, a bladder diary, and a list of questions for patients to ask physicians. Download Fresh Approach Kit.

The Vantage ProgramSM provides valuable information and exclusive savings for your patients. Click here to learn more.
Important Safety Information

VESIcare tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily.

As with other anticholinergic agents, VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product.

As with other anticholinergic agents, VESIcare should be administered with caution to patients with bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal or hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended.

In placebo-controlled studies, the most common adverse events reported by patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and dyspepsia (1.4%, 3.9%, 1.0%) with VESIcare 5 mg, 10 mg, and placebo, respectively.

The overall rate of serious adverse events was 2%. For the 10-mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction, and one intestinal obstruction). For the 5-mg dose, one case of angioneurotic edema was reported.

Complete Prescribing Information for VESIcare

Astellas
VESIcare is a registered trademark of Astellas Pharma Inc.

This site is intended for US residents only.
© 2005-2007 Astellas Pharma US, Inc. and The GlaxoSmithKline Group of Companies
All rights reserved.
Legal Notices | Privacy Statement | Contact Us | Site Map